At the 2017 San Antonio Breast Cancer Symposium (SABCS), Agendia Inc, Irvine, Calif, presented extensive new data highlighting the value of its MammaPrint 70-gene breast cancer risk-of-recurrence test and BluePrint breast cancer molecular subtyping test. The company presented a total of 11 posters and discussion sessions at the conference.
The posters and presentations featured new data from the I-Spy 2 trial of neoadjuvant and personalized adaptive novel agents to treat breast cancer; and the Impact trial, a prospective registry for measuring the impact of MammaPrint on adjuvant and neoadjuvant treatment in breast cancer patients. The company also presented cost-effectiveness and performance data across patient populations of different ages, and those affected by obesity and other metabolic factors.
One highlight was an oral presentation that showed the first long-term survival results from the I-Spy 2 trial for patients preselected by MammaPrint.
William Audeh, MD, MS, Agendia.
“The breadth and depth of the new data being presented at SABCS clearly demonstrates the broad application of MammaPrint and BluePrint in helping to guide breast cancer treatment decisions in a wide range of patient populations,” says William Audeh, MD, chief medical officer at Agendia.
For more information, visit Agendia.
